“Many of the studies that are built off of our increased understanding of the disease, as well as new technologies, have now taken hold,” says Todd Sherer, PhD, CEO of The Michael J. Fox Foundation. “We might see them in a relatively short time getting to people with Parkinson’s.”
That’s the optimism seen in the field today, as new ways to deliver the current gold standard medication may help avoid motor fluctuations; therapies that may stop or slow Parkinson’s progression are in clinical testing; and researchers are learning more about the biology of the disease.
Watch our webinar on this year’s progress in Parkinson’s research.
In our latest podcast Dr. Sherer speaks about these developments and what they mean for people living with Parkinson’s.
“We have a lot of opportunities but we have to stay clearly focused on the challenges that we face so that we can make sure that we have the greatest chance for success,” he says.
Dr. Sherer and other panelists discussed 2014 Parkinson’s research progress and how we’ll build on this year’s milestones in our Third Thursdays Webinar on December 18. Watch now.
Subscribe to our podcast series for more Parkinson’s research updates on the go.
